Tempus is a health technology company that uses data and AI to support precision medicine, diagnostics, and genomic sequencing. It serves oncology and other clinical areas, with tools aimed at improving patient care and drug discovery.
UpMarket does not offer Tempus shares. This page covers Tempus's history before it went public.
Tempus became a public company on June 14, 2024 and trades on Nasdaq as TEM. UpMarket does not offer Tempus shares. This page covers Tempus's valuation and funding history before it went public.
Tempus listed on Nasdaq under the ticker TEM on June 14, 2024.
See how Tempus's private-market valuation changed across funding rounds before it went public.
See reported funding rounds and revenue figures on this page, with their sources.
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
Tempus said its data backlog reached record levels, while MRD volumes continued to surge in the latest bull case. One cited 2026 outlook models about $1.59 billion in revenue, implying continued expansion in diagnostics and data services.
Tempus is described as using proprietary AI foundation models to “weaponize” its clinical data asset, supported by a large and growing data backlog. The investment case argues that this data moat is a key differentiator in precision medicine workflows.
Healthcare IT spending is projected to grow at a 15.4% CAGR from 2024 to 2031, signaling a large addressable market backdrop. Tempus is positioned to benefit as AI healthcare adoption and data-driven diagnostics expand.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
Browse the directory →UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. Tempus became a public company on June 14, 2024 and trades on Nasdaq under the ticker TEM. UpMarket does not offer Tempus shares.
Tempus's share price is set on the public market under the ticker TEM. The prices shown on this page are historical private-market prices from before it went public.
No. Tempus is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Tempus is now publicly traded, so its shares can be bought and sold on Nasdaq and their price can change significantly. Review Tempus's public filings and consult a financial advisor before investing. UpMarket does not offer Tempus shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Tempus became a public company on June 14, 2024, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer Tempus shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Tempus's valuation is now set by its public share price on Nasdaq. The figures on this page show its valuation history before it went public.
Tempus is a health technology company using data, AI, diagnostics, and genomic sequencing across oncology and other clinical areas, with $693M in 2024 revenue; record data growth and rising MRD volumes are key catalysts. Tempus is now a public company, and UpMarket does not offer its shares.